{
    "ticker": "PTIX",
    "name": "Proteostasis Therapeutics, Inc.",
    "description": "Proteostasis Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of cystic fibrosis and other diseases associated with protein misfolding and dysfunction. Founded in 2010, the company\u2019s mission is to restore protein homeostasis, which is critical for the proper functioning of cells. Proteostasis employs a proprietary platform that leverages small molecules to enhance the body's natural protein quality control mechanisms. The company's lead product candidate, PTI-125, is designed to improve the function of the CFTR protein, which is defective in cystic fibrosis patients. Additionally, the company is exploring various therapeutic avenues for other protein misfolding diseases, such as Alzheimer's and Parkinson's. By targeting the underlying mechanisms of these diseases, Proteostasis aims to provide more effective treatment options for patients. The company is committed to advancing its pipeline through robust clinical trials and partnerships with research institutions and pharmaceutical companies, thereby accelerating the development of its therapies. With a team of experienced scientists and industry professionals, Proteostasis Therapeutics is poised to make significant contributions to the field of biotechnology and improve the lives of patients suffering from debilitating diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.proteostasis.com",
    "ceo": "Meghan FitzGerald, DrPH",
    "social_media": {
        "twitter": "https://twitter.com/proteostasis",
        "linkedin": "https://www.linkedin.com/company/proteostasis-therapeutics/"
    },
    "investor_relations": "https://ir.proteostasis.com",
    "key_executives": [
        {
            "name": "Meghan FitzGerald, DrPH",
            "position": "CEO"
        },
        {
            "name": "Sandeep K. Ghosh",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PTI-125"
            ]
        }
    ],
    "seo": {
        "meta_title": "Proteostasis Therapeutics, Inc. | Innovating Cystic Fibrosis Treatments",
        "meta_description": "Explore Proteostasis Therapeutics, Inc., a leader in biotechnology focused on developing therapies for cystic fibrosis and protein misfolding diseases.",
        "keywords": [
            "Proteostasis",
            "Cystic Fibrosis",
            "Biotechnology",
            "PTI-125",
            "Protein Misfolding",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What is Proteostasis Therapeutics known for?",
            "answer": "Proteostasis Therapeutics is known for its development of therapies for cystic fibrosis and other diseases related to protein misfolding."
        },
        {
            "question": "Who is the CEO of Proteostasis Therapeutics?",
            "answer": "Meghan FitzGerald, DrPH is the CEO of Proteostasis Therapeutics, Inc."
        },
        {
            "question": "Where is Proteostasis headquartered?",
            "answer": "Proteostasis is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is the lead product candidate of Proteostasis?",
            "answer": "The lead product candidate of Proteostasis is PTI-125, aimed at improving CFTR protein function in cystic fibrosis patients."
        },
        {
            "question": "When was Proteostasis Therapeutics founded?",
            "answer": "Proteostasis Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "VRTX",
        "ALNY",
        "PTCT",
        "SAGE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "REGN"
    ]
}